Eiger BioPharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 14, 2023 at 04:05 pm EDT
Eiger BioPharmaceuticals, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 4.64 million compared to USD 4.09 million a year ago. Net loss was USD 20.7 million compared to USD 21.88 million a year ago. Basic loss per share from continuing operations was USD 14.1 compared to USD 15.3 a year ago.
For the six months, revenue was USD 8.76 million compared to USD 6.76 million a year ago. Net loss was USD 43.48 million compared to USD 44.53 million a year ago. Basic loss per share from continuing operations was USD 29.4 compared to USD 34.2 a year ago.